Overview
FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology, published by Irbis (Czechia) (Russia), published 248 papers in 2021–2025, and these papers have received 737 citations so far. Its h-index is 15 and its two-year mean citedness is 1.13. On the ITS Journal Score it ranks #17,608 of 62,158 ranked journals and #623 of 1,830 in Economics, Econometrics and Finance.
Key figures
Citations are those received so far by the papers published in these years, so the most recent years have had less time to collect them. Two-year mean citedness is OpenAlex's measure of how often recent papers are cited; it is similar in idea to, but not the same as, an impact factor. Citation impact trend compares how often a journal's 2024-25 papers are cited with how often its 2021-22 papers were cited, each measured against all ranked journals' papers of the same years, so newer papers are not at a disadvantage. "Not enough papers" or "Not enough data" means fewer than 50 papers in one of the two-year periods (or fewer than 50 citations to the earlier papers). Values above +300% or below -90% are shown as "+300% or more" or "-90% or less": such extreme values come from very low citation counts for the earlier papers.
Papers and citations by year
| Year | Papers | Citations so far to that year's papers | Open-access papers |
|---|---|---|---|
| 2020 | 39 | 184 | 39 |
| 2021 | 46 | 272 | 46 |
| 2022 | 43 | 159 | 43 |
| 2023 | 65 | 156 | 65 |
| 2024 | 45 | 81 | 45 |
| 2025 | 49 | 69 | 49 |
What it publishes
The leading research topics of its papers (OpenAlex topic classification). Select a topic to find other journals that publish on it.
Similar journals
Ranked journals that publish on the same topics.
| Journal | Field | Score | Papers 2021–2025 | Open access |
|---|---|---|---|---|
| Healthcare Management News Views Education Bulletin of VSHOUZ | Medicine | 37.6 | 161 | 61% |
| PharmacoEconomics | Economics, Econometrics and Finance | 77.9 | 580 | 78% |
| City Healthcare | Medicine | 39.7 | 304 | 100% |
| Problems of Social Hygiene Public Health and History of Medicine | Medicine | 47.3 | 1,175 | 29% |
| Expert Review of Pharmacoeconomics & Outcomes Research | Economics, Econometrics and Finance | 69.4 | 582 | 45% |
| Value in Health | Economics, Econometrics and Finance | 64.4 | 21,155 | 49% |
| Journal of Market Access & Health Policy | Economics, Econometrics and Finance | 61.8 | 158 | 100% |
| International Journal of Technology Assessment in Health Care | Economics, Econometrics and Finance | 65.0 | 1,630 | 96% |
Compare with similar journals (side by side with the two closest journals above)
Identity and sources
- ISSN-L: 2070-4909
- Print ISSN: 2070-4909
- Electronic ISSN: 2070-4933
- Publisher: Irbis (Czechia)
- Listed in DOAJ: Yes (checked against DOAJ)
- Crossref: Not yet checked
- OpenAlex: S2764615430
- Journal website: www.pharmacoeconomics.ru
Figures come from OpenAlex (papers, citations, h-index, topics), Crossref (ISSN check) and DOAJ (open-access listing and fees). They change as records are corrected, so treat them as a dated snapshot. This page does not state whether the journal is indexed in Scopus, Web of Science or PubMed.
Questions
What is the ITS Journal Score of FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology?
It is 52.7 out of 100, which places it #17,608 among ranked journals. The score combines citation impact (45%), h-index (35%) and size (20%) from open OpenAlex data.
What is the impact factor of FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology?
This site does not publish Journal Impact Factors, which belong to Clarivate. As an open alternative, its two-year mean citedness in OpenAlex is 1.13.
Is FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology open access?
100% of its papers from 2021–2025 are recorded as open access, and it is listed in DOAJ.
Does FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology charge a publication fee?
DOAJ records an article processing charge of 15,000 RUB. Check the journal's website for the current fee and any waivers.